AstraZeneca: Oddo BHF on hold, nudges up TP

(CercleFinance.com) - Oddo BHF maintains its "neutral" rating on AstraZeneca shares, with a target price raised from 12,100 pence to 12,500 pence following its CMD.


The analyst reports that management expects to achieve revenues of $80bn by 2030, which is extremely ambitious, given that the consensus was expecting $69.1bn.

This CMD reminded the market of the extent of the company's pipeline. AZN undoubtedly has one of the finest clinical portfolios in the industry, the broker says.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.